- Axe Compute Sells Helomics to DataMEDS, Completes Shift to Pure-Play GPU-as-a-Service
Axe Compute Inc. has sold its Helomics artificial intelligence cancer diagnostics laboratory business to DataMEDS AI in an all-stock transaction, completing the company’s transition from its former healthcare-focused identity into a pure-play provider of GPU infrastructure for artificial intelligence workloads.
The Pittsburgh-based company, which trades on Nasdaq under the ticker AGPU, said it transferred its wholly owned Helomics subsidiary in exchange for common shares and common share equivalents of DataMEDS AI, giving Axe Compute continued economic exposure to the oncology business while allowing management to concentrate capital and operations on its expanding neocloud platform.
The companies did not disclose the number or value of DataMEDS shares issued as consideration in the announcement.
Helomics is a Pittsburgh-based functional precision medicine oncology platform that applies artificial intelligence to real-world tumour data to support cancer treatment decisions and pharmaceutical drug discovery.
The business represents the final operating asset remaining from Axe Compute’s former identity as Predictive Oncology Inc., before the company changed its name in December 2025 and shifted its strategy towards high-performance computing infrastructure.
For Axe Compute, the disposal effectively closes that transformation.
“This transaction is the final chapter of Axe Compute’s transformation into a focused, pure-play neocloud GPU-as-a-Service company,” Chief Executive Christopher Miglino said.
“Just as important, we structured it so that our shareholders keep a stake in the future of AI Helomics.”
Rather than making a clean cash exit from the healthcare business, Axe Compute is effectively exchanging direct ownership of Helomics for an equity interest in DataMEDS, allowing shareholders to retain potential upside if the oncology platform expands under its new owner.
Mr Miglino said DataMEDS’ health-data and artificial intelligence platform placed it in a stronger position to scale what Axe Compute’s Pittsburgh team had developed, while freeing Axe Compute to direct its resources towards the rapidly expanding demand for AI computing capacity.
“Rather than simply exiting the business, we are becoming an investor in DataMEDS — a company whose health-data and AI platform makes it exceptionally well positioned to scale what our team in Pittsburgh built — while we dedicate the entirety of our team, capital, and operations to meeting the accelerating demand for AI compute,” he said.
For DataMEDS, which trades under the ticker MEDS, the transaction gives the health technology company a direct entry into oncology.
The Tampa-based company, formerly known as Wellgistics Health, combines technology, pharmacy, pharmaceutical-adjacent and telemedicine operations within a broader healthcare platform.
Its existing technology includes the EinsteinRx artificial intelligence platform and PharmacyChain, a blockchain-enabled smart-contract system, alongside its Health Lives Here mobile application. Its Corexa Health subsidiary provides pharmacy and related distribution services.
Gerald Commissiong, Interim Co-Chief Executive of DataMEDS, said the Helomics transaction would broaden the company’s healthcare ambitions.
“We are thrilled to have completed this strategic transaction that thrusts DataMEDS into the field of oncology, where we know there is a tremendous need to improve patient outcomes, using our data driven approach to healthcare,” he said.
The transaction reflects a sharp strategic separation between two different applications of artificial intelligence.
Helomics uses AI within precision oncology, analysing tumour and healthcare data to support treatment and drug-development decisions.
Axe Compute’s future, by contrast, is increasingly centred on providing the underlying computing infrastructure required by companies developing and deploying artificial intelligence applications.
The company describes itself as a neocloud AI infrastructure platform designed to give enterprises and AI developers greater flexibility over hardware, geography and deployment models.
Its business is organised around two principal offerings.
Axe Compute Access provides customers with access to high-performance GPU infrastructure across multiple global locations, while Axe Compute Build focuses on the design, deployment, ownership and operation of large-scale dedicated AI infrastructure.
The company says its model is intended to address one of the critical constraints in the rapidly expanding artificial intelligence market: access to sufficient computing capacity.
AI developers increasingly require large quantities of specialised graphics processing units to train and operate increasingly sophisticated models. That has created a market for infrastructure providers capable of supplying GPU capacity without customers necessarily having to build and operate their own data centres.
By disposing of Helomics, Axe Compute is effectively removing the final operational link to its healthcare origins and concentrating its corporate structure around that infrastructure thesis.
The all-stock structure, however, means the company has not completely severed its economic relationship with Helomics.
Its DataMEDS equity gives Axe Compute exposure to the future value of the oncology operation without requiring it to continue running the business directly.
That structure also introduces a different set of risks. The ultimate value Axe Compute receives will depend partly on the market performance and liquidity of DataMEDS shares, while the commercial success of Helomics under its new owner remains uncertain.
Axe Compute itself cautioned that the value of the DataMEDS securities received could fluctuate and that anticipated benefits from the transaction may not necessarily be realised.
The company also identified risks surrounding its ability to grow compute-services revenue, maintain Nasdaq listing compliance and execute its broader infrastructure strategy.
Further financial and contractual details of the transaction are expected to be disclosed in a Form 8-K filing with the US Securities and Exchange Commission.
The sale nevertheless represents a clear strategic milestone.
Axe Compute has moved from a company built around AI-enabled healthcare diagnostics to one whose investment proposition rests almost entirely on supplying the computational infrastructure required by the wider artificial intelligence economy.
DataMEDS, meanwhile, is moving in the opposite direction deeper into applied healthcare AI by acquiring a platform with an established oncology focus.
For investors, the transaction therefore amounts to more than a disposal of a legacy subsidiary.
It separates two distinct AI strategies: one company betting on the infrastructure required to power increasingly compute-intensive artificial intelligence, and the other expanding the use of AI directly within healthcare and oncology.
With Helomics now outside its operating structure, Axe Compute’s next test will be whether the capital and management attention released by the sale can translate into sustained growth in GPU-as-a-Service the business that now defines the company’s future.
